T
1.43
-0.15 (-9.49%)
| Previous Close | 1.58 |
| Open | 1.60 |
| Volume | 426,040 |
| Avg. Volume (3M) | 647,108 |
| Market Cap | 167,092,640 |
| Price / Book | 85.67 |
| 52 Weeks Range | |
| Earnings Date | 23 Jun 2025 - 8 Jul 2025 |
| Diluted EPS (TTM) | -0.130 |
| Total Debt/Equity (MRQ) | 9.65% |
| Current Ratio (MRQ) | 0.850 |
| Operating Cash Flow (TTM) | -3.91 M |
| Levered Free Cash Flow (TTM) | -8.99 M |
| Return on Assets (TTM) | -69.58% |
| Return on Equity (TTM) | -181.23% |
Market Trend
| Short Term | Medium Term | ||
| Industry | Biotechnology (US) | Bearish | Bearish |
| Biotechnology (Global) | Bearish | Bearish | |
| Stock | Tiziana Life Sciences Ltd | Mixed | Mixed |
AIStockmoo Score
-1.0
| Analyst Consensus | -2.0 |
| Insider Activity | NA |
| Price Volatility | -4.5 |
| Technical Moving Averages | 0.0 |
| Technical Oscillators | 2.5 |
| Average | -1.00 |
|
Tiziana Life Sciences Ltd is a clinical-stage biotechnology company that specializes in the developing transformative therapies for neurodegenerative and lung diseases. Its clinical pipeline includes drug assets for Secondary Progressive Multiple Sclerosis, ALS. Alzheimer's, Crohn's Disease and KRAS+ NSCLC. Tiziana is led by a team of qualified executives with extensive drug development and commercialization experience. |
|
| Sector | Healthcare |
| Industry | Biotechnology |
| Investment Style | Small Value |
| % Held by Insiders | 35.56% |
| % Held by Institutions | 0.89% |
Ownership
| Name | Date | Shares Held |
|---|---|---|
| Dauntless Investment Group, Llc | 31 Mar 2025 | 1,739,574 |
| Zhang Financial Llc | 31 Mar 2025 | 96,260 |
| Kovitz Investment Group Partners, Llc | 31 Mar 2025 | 79,365 |
| Hrt Financial Lp | 31 Mar 2025 | 70,366 |
| Ewa, Llc | 31 Mar 2025 | 47,601 |
| Bison Wealth, Llc | 31 Dec 2024 | 42,795 |
| Bison Wealth, Llc | 31 Mar 2025 | 42,795 |
No data within this time range.
No data within this time range.
The support, resistance and trendline levels presented has been generated by an artificial intelligence (AI) model and should be interpreted with caution.
Portfolio
| Realized Profit | - |
| Unrealized Profit | - |
| Dividend Received 2025 | - |
| Total Profit | - |
| Avg. Return | - |
| Quantity (Buy) | - |
| Avg. Price (Buy) | - |
| Quantity (Sold) | - |
| Avg. Price (Sold) | - |